Runners.
Conditions
Interventions
Intervention 1: Intervention group: during the two weeks, the intervention group will receive two packets of powder containing 13 grams of date seed powder with high-intensity interval training. One p
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Age range 18 to 35 years old Doing two exercises for at least 3 days a week (240 minutes per week) during the last 2 years Complete health (confirmed by PAR-Q questionnaire under the supervision of a doctor) The body mass index of 18.5-25 Not receiving date seed powder in the last 3 months Not doing high-intensity interval training during the last 3 months Willingness to cooperate
Exclusion criteria
Exclusion criteria: Musculoskeletal injury Smoking, alcohol consumption Hormone therapy Long-term use of drugs Use of dietary supplements Pregnancy, lactation Diabetes, anemia (Hb <13g / dl), cardiovascular disease , infectious diseases, malignancy and cognitive disorders Intake of antihypertensives, diuretics and antidiabetics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total antioxidant capacity. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Malondialdehyde. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Superoxide dismutase. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;High-sensitivity C-reactive Protein. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Interleukin 10. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Interleukin 6. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Creatine Kinase. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Lactate dehydrogenase. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Sport performance. Timepoint: At baseline and two weeks after baseline. Method of measurement: questionnaire.;Insulin. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Glucose. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Insulin-like Growth Factor-1. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Adiponectin. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Tumor necrosis factor alpha. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Myoglobin. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Irisin. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Cortisol. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Brain-Derived Neurotrophic Factor. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;F2-isoprostanes. Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;8-Oxo-2'-deoxyguanosine. Timepoint: At baseline and two weeks after baseline. Method o | — |
Secondary
| Measure | Time frame |
|---|---|
| Nutritional status (energy and macronutrients intake). Timepoint: At baseline and two weeks after baseline. Method of measurement: 3-days food intake record.;Body composition. Timepoint: At baseline and two weeks after baseline. Method of measurement: (BIA, BC-418 MA).;CBC (Complete blood count). Timepoint: At baseline and two weeks after baseline. Method of measurement: Kit.;Sleep. Timepoint: At baseline and two weeks after baseline. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParvin Dehghan
Tabriz University of Medical Sciences
Outcome results
None listed